文献速递浆细胞疾病

衰弱亚组决定老年新诊断多发性骨髓瘤患者的异质性结局:HOVON 143 试验长期随访

Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial.
PubMed 文献 · Blood Adv · 2025-01-01

HOVON 143 试验是首个采用国际骨髓瘤工作组衰弱指数(IMWG-FI)专为衰弱新诊断多发性骨髓瘤(NDMM)患者设计的试验,中位随访超过5年。患者接受9个诱导周期伊沙佐米、达雷妥尤单抗和低剂量地塞米松,随后维持治疗至进展最长2年。中位无进展生存期(PFS)为13.8个月,中位总生存期(OS)为34.0个月;基于年龄以外的老年损伤和合并症划分的衰弱亚组结局异质性明显。

要点

  • HOVON 143 试验首个采用 IMWG-FI 专为衰弱 NDMM 患者设计,中位随访超过5年。
  • 中位 PFS 为13.8个月,中位 OS 为34.0个月。
  • 极度衰弱和因损伤而衰弱的患者早期复发相关及非复发相关死亡率均高于仅因年龄衰弱的患者。

核心结论

  • 基于年龄以外的老年损伤和合并症划分的衰弱亚组结局异质性明显,提示需要更精确的衰弱定义以识别早期死亡风险最高的患者。

研究设计与样本

  • HOVON 143 试验是首个使用 IMWG-FI 专为衰弱 NDMM 患者设计的试验,中位随访超过5年。
  • 符合 IMWG-FI 衰弱标准的患者接受9个诱导周期伊沙佐米、达雷妥尤单抗和低剂量地塞米松,随后维持治疗至进展最长2年。

主要发现

  • 中位 PFS 为13.8个月,中位 OS 为34.0个月。
  • 极度衰弱患者和因损伤而衰弱的患者早期复发相关及非复发相关死亡率均高于仅因年龄衰弱的患者。

关键数值与推荐

  • 衰弱定义采用国际骨髓瘤工作组衰弱指数(IMWG-FI)。
  • 诱导方案为伊沙佐米、达雷妥尤单抗和低剂量地塞米松共9个周期,维持治疗至进展最长2年。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Frailty, rather than age alone, is a key determinant of outcomes in older patients with multiple myeloma (MM), yet frailty assessments are often lacking in clinical trials. Consequently, data on the efficacy and tolerability of novel treatments in frail patients remain scarce. Moreover, there is substantial heterogeneity among frail patients, with some classified as frail solely due to age (>80 years) and others due to geriatric impairments and/or comorbidities. To our knowledge, the HOVON 143 trial was the first trial that was specifically designed for frail patients with newly diagnosed MM (NDMM) using the International Myeloma Working Group Frailty Index (IMWG-FI). After a median follow-up of >5 years, we report the long-term progression-free survival (PFS) and overall survival (OS) outcomes, with detailed analyses of frail subgroups. Patients who were classified as frail according to the IMWG-FI were treated with 9 induction cycles of ixazomib, daratumumab, and low-dose dexamethasone, followed by maintenance therapy until progression for a maximum of 2 years. Median PFS was 13.8 months, and median OS was 34.0 months. However, frail subgroup analyses based on geriatric impairments and comorbidities besides age revealed pronounced heterogeneity in outcomes. Both early relapse-related and nonrelapse-related mortality rates were higher in ultrafrail patients and patients who were frail due to impairments than in patients who were frail based on age alone. These findings highlight the need for a more precise frailty definition to identify patients at the highest risk of early mortality. This trial was registered at www.clinicaltrialsregister.eu as EudraCT #2016-002600-90.

来源:Blood Adv,查看原文。版权归原作者所有。

引用

  1. Smits F, Groen K, Levin MD, et al. Frail subgroups determine heterogeneous outcomes in older patients with NDMM: long-term follow-up of the HOVON 143 trial. Blood Adv. 2025. PMID: 40845265. doi:10.1182/bloodadvances.2025017394

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。